Ginkgo Bioworks Holdings Inc
NYSE:DNA
Ginkgo Bioworks Holdings Inc
NYSE:DNA
Price:
6.78
USD
-0.29%
Market Cap:
$399.5m
Relative Value
The Relative Value of one
DNA
stock under the Base Case scenario is
5.13
USD.
Compared to the current market price of 6.78 USD,
Ginkgo Bioworks Holdings Inc
is
Overvalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DNA
Relative Value
Base Case
5.13
USD
Overvaluation 24%
Multiples Across Competitors
DNA Competitors Multiples
Ginkgo Bioworks Holdings Inc Competitors
Ginkgo Bioworks Holdings Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Ginkgo Bioworks Holdings Inc
NYSE:DNA
|
394.6m USD | 2.3 | -1.3 | 0.1 | 0.1 | |
| US |
|
Sherwin-Williams Co
NYSE:SHW
|
80B USD | 3.4 | 31.2 | 20.2 | 23.8 | |
| US |
|
Ecolab Inc
NYSE:ECL
|
77.2B USD | 4.8 | 37.1 | 21.5 | 28.8 | |
| JP |
|
Shin-Etsu Chemical Co Ltd
TSE:4063
|
12.2T JPY | 4.8 | 25.1 | 12.3 | 17 | |
| JP |
Y
|
Yasuhara Chemical Co Ltd
TSE:4957
|
10.8T JPY | 1 | 10.5 | 5.8 | 7.1 | |
| CN |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
248.2B CNY | 1.4 | 22.4 | 19.6 | 19.6 | |
| CH |
|
Givaudan SA
SIX:GIVN
|
26.2B CHF | 3.5 | 24.4 | 17 | 21.6 | |
| DK |
|
Novozymes A/S
CSE:NZYM B
|
165.6B DKK | 9.3 | 54.8 | 28.9 | 37.9 | |
| IN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
2.1T INR | 6.1 | 55.2 | 33.1 | 40.7 | |
| US |
|
PPG Industries Inc
NYSE:PPG
|
23B USD | 1.5 | 14.7 | 10.3 | 12.8 | |
| CH |
|
Sika AG
F:SIKA
|
19.9B EUR | 1.6 | 17.3 | 10.2 | 14.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
